Table 2.
Incidence of adverse events occurring in > 10% of patients and two or more patients within at least one treatment group (safety population)
| Preferred terma | Placebo group (n = 9) | Liarozole 75 mg group (n = 27) | Liarozole 150 mg group (n = 28) | Liarozole, combined groups (n = 55) |
|---|---|---|---|---|
| Nasopharyngitis | 3 (22) | 2 (7) | 4 (11) | 6 (9) |
| Alopecia | 1 (11) | 1 (4) | 5 (11) | 6 (7) |
| Fatigue | – | 3 (11) | 3 (11) | 6 (11) |
| Arthralgia | – | 2 (7) | 4 (11) | 6 (9) |
| Headache | – | 2 (7) | 4 (11) | 6 (9) |
| Nausea | 2 (22) | 2 (7) | 1 (4) | 3 (5) |
| Pruritus | – | 3 (11) | 2 (7) | 5 (9) |
| Epistaxis | – | 4 (11) | 1 (4) | 5 (7) |
| Cheilitis | – | 3 (11) | 2 (7) | 5 (9) |
| Creatine phosphokinase increased | – | 1 (4) | 3 (11) | 4 (7) |
| Hyperhidrosis | – | 3 (11) | – | 3 (5) |
| Skin exfoliation | – | 3 (11) | – | 3 (5) |
a
Values shown are the number of events (percentage of patients with event).